Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2003 Nov;40(11):802–806. doi: 10.1136/jmg.40.11.802

Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation

C Warren 1, L James 1, R Ramsden 1, A Wallace 1, M Baser 1, J Varley 1, D Evans 1
PMCID: PMC1735326  PMID: 14627667

Abstract

Background: Schwannomas are benign tumours of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). The NF2 gene is a tumour suppressor on chromosome 22. Loss of expression of the NF2 protein product, merlin, is universal in both sporadic and NF2 related schwannomas. The GTPase signalling molecules RhoA and Rac1 regulate merlin function, but to date only mutation in the NF2 gene has been identified as a causal event in schwannoma formation.

Methods: Comparative genomic hybridisation (CGH) was used to screen 76 vestibular schwannomas from 76 patients (66 sporadic and 10 NF2 related) to identify other chromosome regions that may harbour genes involved in the tumorigenesis.

Results: The most common change was loss on chromosome 22, which was more frequent in sporadic than in NF2 related tumours. Importantly, eight tumours (10%) showed gain of copy number on chromosome 9q34. Each of the two NF2 patients who had received stereotactic radiotherapy had non-chromosome 22 changes, whereas only one of eight non-irradiated NF2 patients had any chromosome changes. Three tumours had gain on 17q, which has also been reported in malignant peripheral nerve sheath tumours that are associated with neurofibromatosis type 1. Other sites that were identified in three or fewer tumours were regions on chromosomes 10, 11, 13, 16, 19, 20, X, and Y.

Conclusions: These findings should be verified using techniques that can detect smaller genetic changes, such as microarray-CGH.

Full Text

The Full Text of this article is available as a PDF (186.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albright C. F., Giddings B. W., Liu J., Vito M., Weinberg R. A. Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase. EMBO J. 1993 Jan;12(1):339–347. doi: 10.1002/j.1460-2075.1993.tb05662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antinheimo J., Sallinen S. L., Sallinen P., Haapasalo H., Helin H., Horelli-Kuitunen N., Wessman M., Sainio M., Jäskeläinen J., Carpén O. Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir (Wien) 2000;142(10):1099–1105. doi: 10.1007/s007010070036. [DOI] [PubMed] [Google Scholar]
  3. Baser M. E., Evans D. G., Jackler R. K., Sujansky E., Rubenstein A. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer. 2000 Feb;82(4):998–998. doi: 10.1054/bjoc.1999.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans D. G., Blair V., Strachan T., Lye R. H., Ramsden R. T. Variation of expression of the gene for type 2 neurofibromatosis: absence of a gender effect on vestibular schwannomas, but confirmation of a preponderance of meningiomas in females. J Laryngol Otol. 1995 Sep;109(9):830–835. doi: 10.1017/s0022215100131445. [DOI] [PubMed] [Google Scholar]
  5. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  6. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Teare D., Newton V., Strachan T., Ramsden R., Harris R. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841–846. doi: 10.1136/jmg.29.12.841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. G., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998 Jun;35(6):450–455. doi: 10.1136/jmg.35.6.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forozan F., Karhu R., Kononen J., Kallioniemi A., Kallioniemi O. P. Genome screening by comparative genomic hybridization. Trends Genet. 1997 Oct;13(10):405–409. doi: 10.1016/s0168-9525(97)01244-4. [DOI] [PubMed] [Google Scholar]
  9. Garcia Juan Luis, Tardio Juan C., Gutierrez Norma Carmen, Gonzalez Maria Belen, Polo Jose Ramon, Hernandez Jesus Maria, Menarguez Javier. Chromosomal imbalances identified by comparative genomic hybridization in sporadic parathyroid adenomas. Eur J Endocrinol. 2002 Feb;146(2):209–213. doi: 10.1530/eje.0.1460209. [DOI] [PubMed] [Google Scholar]
  10. Giovannini M., Robanus-Maandag E., van der Valk M., Niwa-Kawakita M., Abramowski V., Goutebroze L., Woodruff J. M., Berns A., Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000 Jul 1;14(13):1617–1630. [PMC free article] [PubMed] [Google Scholar]
  11. Goeze Almut, Schlüns Karsten, Wolf Guenter, Thäsler Zsuzsanna, Petersen Simone, Petersen Iver. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol. 2002 Jan;196(1):8–16. doi: 10.1002/path.1009. [DOI] [PubMed] [Google Scholar]
  12. Hirao M., Sato N., Kondo T., Yonemura S., Monden M., Sasaki T., Takai Y., Tsukita S., Tsukita S. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol. 1996 Oct;135(1):37–51. doi: 10.1083/jcb.135.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hsu S. M., Raine L., Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 1981 Jun;75(6):816–821. doi: 10.1093/ajcp/75.6.816. [DOI] [PubMed] [Google Scholar]
  14. Jacoby L. B., MacCollin M., Barone R., Ramesh V., Gusella J. F. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer. 1996 Sep;17(1):45–55. doi: 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  15. Jacoby L. B., MacCollin M., Louis D. N., Mohney T., Rubio M. P., Pulaski K., Trofatter J. A., Kley N., Seizinger B., Ramesh V. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994 Mar;3(3):413–419. doi: 10.1093/hmg/3.3.413. [DOI] [PubMed] [Google Scholar]
  16. James L. A. Comparative genomic hybridization as a tool in tumour cytogenetics. J Pathol. 1999 Mar;187(4):385–395. doi: 10.1002/(SICI)1096-9896(199903)187:4<385::AID-PATH290>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  17. James L. A., Kelsey A. M., Birch J. M., Varley J. M. Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br J Cancer. 1999 Sep;81(2):300–304. doi: 10.1038/sj.bjc.6990691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kallioniemi A., Kallioniemi O. P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992 Oct 30;258(5083):818–821. doi: 10.1126/science.1359641. [DOI] [PubMed] [Google Scholar]
  19. Khan J., Parsa N. Z., Harada T., Meltzer P. S., Carter N. P. Detection of gains and losses in 18 meningiomas by comparative genomic hybridization. Cancer Genet Cytogenet. 1998 Jun;103(2):95–100. doi: 10.1016/s0165-4608(97)00394-4. [DOI] [PubMed] [Google Scholar]
  20. Kim H. A., Rosenbaum T., Marchionni M. A., Ratner N., DeClue J. E. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene. 1995 Jul 20;11(2):325–335. [PubMed] [Google Scholar]
  21. Knösel Thomas, Petersen Simone, Schwabe Holger, Schlüns Karsten, Stein Ulrike, Schlag Peter Michael, Dietel Manfred, Petersen Iver. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002 Feb;440(2):187–194. doi: 10.1007/s004280100493. [DOI] [PubMed] [Google Scholar]
  22. Matsui T., Maeda M., Doi Y., Yonemura S., Amano M., Kaibuchi K., Tsukita S., Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998 Feb 9;140(3):647–657. doi: 10.1083/jcb.140.3.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. doi: 10.1097/00006123-199605000-00004. [DOI] [PubMed] [Google Scholar]
  24. Mechtersheimer G., Otaño-Joos M., Ohl S., Benner A., Lehnert T., Willeke F., Möller P., Otto H. F., Lichter P., Joos S. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer. 1999 Aug;25(4):362–369. [PubMed] [Google Scholar]
  25. Mitchell E. L., Jones D., White G. R., Varley J. M., Santibanez Koref M. F. Determination of the gene order of the three loci CD2, NGFB, and NRAS at human chromosome band 1p13 and refinement of their localisation at the subband level by fluorescence in situ hybridisation. Cytogenet Cell Genet. 1995;70(3-4):183–185. doi: 10.1159/000134028. [DOI] [PubMed] [Google Scholar]
  26. Mohyuddin A., Vokurka E. A., Evans D. G. R., Ramsden R. T., Jackson A. Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas? Clin Otolaryngol Allied Sci. 2003 Apr;28(2):85–90. doi: 10.1046/j.1365-2273.2003.00670.x. [DOI] [PubMed] [Google Scholar]
  27. Mérel P., Hoang-Xuan K., Sanson M., Bijlsma E., Rouleau G., Laurent-Puig P., Pulst S., Baser M., Lenoir G., Sterkers J. M. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. doi: 10.1002/gcc.2870120206. [DOI] [PubMed] [Google Scholar]
  28. Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O. Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2001 Apr 27;8(2):85–95. doi: 10.1093/dnares/8.2.85. [DOI] [PubMed] [Google Scholar]
  29. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  30. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  31. Pelton P. D., Sherman L. S., Rizvi T. A., Marchionni M. A., Wood P., Friedman R. A., Ratner N. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene. 1998 Oct 29;17(17):2195–2209. doi: 10.1038/sj.onc.1202141. [DOI] [PubMed] [Google Scholar]
  32. Reed N., Gutmann D. H. Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med. 2001 Apr;7(4):157–162. doi: 10.1016/s1471-4914(01)01955-4. [DOI] [PubMed] [Google Scholar]
  33. Renedo M., Martinez-Delgado B., Arranz E., Garcia M., Urioste M., Martinez-Ramirez A., Rivas C., Cigudosa J. C., Benitez I. Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas. Leukemia. 2001 Oct;15(10):1627–1632. doi: 10.1038/sj.leu.2402248. [DOI] [PubMed] [Google Scholar]
  34. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  35. Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed] [Google Scholar]
  36. Sainio M., Zhao F., Heiska L., Turunen O., den Bakker M., Zwarthoff E., Lutchman M., Rouleau G. A., Jäskeläinen J., Vaheri A. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci. 1997 Sep;110(Pt 18):2249–2260. doi: 10.1242/jcs.110.18.2249. [DOI] [PubMed] [Google Scholar]
  37. Sarlomo-Rikala M., El-Rifai W., Lahtinen T., Andersson L. C., Miettinen M., Knuutila S. Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. Hum Pathol. 1998 May;29(5):476–481. doi: 10.1016/s0046-8177(98)90063-6. [DOI] [PubMed] [Google Scholar]
  38. Schmidt H., Würl P., Taubert H., Meye A., Bache M., Holzhausen H. J., Hinze R. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer. 1999 Jul;25(3):205–211. [PubMed] [Google Scholar]
  39. Shin Masahiro, Ueki Keisuke, Kurita Hiroki, Kirino Takaaki. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet. 2002 Jul 27;360(9329):309–310. doi: 10.1016/S0140-6736(02)09521-1. [DOI] [PubMed] [Google Scholar]
  40. Tikoo A., Varga M., Ramesh V., Gusella J., Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem. 1994 Sep 23;269(38):23387–23390. [PubMed] [Google Scholar]
  41. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  42. Tsukita S., Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997 Feb;9(1):70–75. doi: 10.1016/s0955-0674(97)80154-8. [DOI] [PubMed] [Google Scholar]
  43. Vaheri A., Carpén O., Heiska L., Helander T. S., Jäskeläinen J., Majander-Nordenswan P., Sainio M., Timonen T., Turunen O. The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol. 1997 Oct;9(5):659–666. doi: 10.1016/s0955-0674(97)80119-6. [DOI] [PubMed] [Google Scholar]
  44. Welling D. B. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas). Laryngoscope. 1998 Feb;108(2):178–189. doi: 10.1097/00005537-199802000-00005. [DOI] [PubMed] [Google Scholar]
  45. Wilson C. A., Payton M. N., Elliott G. S., Buaas F. W., Cajulis E. E., Grosshans D., Ramos L., Reese D. M., Slamon D. J., Calzone F. J. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 1997 Jan 9;14(1):1–16. doi: 10.1038/sj.onc.1200924. [DOI] [PubMed] [Google Scholar]
  46. Wolter H., Gottfried H. W., Mattfeldt T. Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization. BJU Int. 2002 Feb;89(3):310–316. doi: 10.1046/j.1464-4096.2001.01722.x. [DOI] [PubMed] [Google Scholar]
  47. Woods Ryan, Friedman J. M., Evans D. Gareth R., Baser Michael E., Joe Harry. Exploring the "two-hit hypothesis" in NF2: tests of two-hit and three-hit models of vestibular schwannoma development. Genet Epidemiol. 2003 May;24(4):265–272. doi: 10.1002/gepi.10238. [DOI] [PubMed] [Google Scholar]
  48. Xiao Guang-Hui, Beeser Alexander, Chernoff Jonathan, Testa Joseph R. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem. 2001 Nov 21;277(2):883–886. doi: 10.1074/jbc.C100553200. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES